MCRB Straddle Strategy
MCRB (Seres Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015.
MCRB (Seres Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $75.1M, a beta of 0.12 versus the broader market, a 52-week range of 6.53-29.98, average daily share volume of 53K, a public-listing history dating back to 2015, approximately 103 full-time employees. These structural characteristics shape how MCRB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.12 indicates MCRB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a straddle on MCRB?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current MCRB snapshot
As of May 15, 2026, spot at $7.69, ATM IV 132.70%, IV rank 29.31%, expected move 38.04%. The straddle on MCRB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on MCRB specifically: MCRB IV at 132.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a MCRB straddle, with a market-implied 1-standard-deviation move of approximately 38.04% (roughly $2.93 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MCRB expiries trade a higher absolute premium for lower per-day decay. Position sizing on MCRB should anchor to the underlying notional of $7.69 per share and to the trader's directional view on MCRB stock.
MCRB straddle setup
The MCRB straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MCRB near $7.69, the first option leg uses a $7.69 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MCRB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MCRB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $7.69 | N/A |
| Buy 1 | Put | $7.69 | N/A |
MCRB straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
MCRB straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on MCRB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on MCRB
Straddles on MCRB are pure-volatility plays that profit from large moves in either direction; traders typically buy MCRB straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
MCRB thesis for this straddle
The market-implied 1-standard-deviation range for MCRB extends from approximately $4.76 on the downside to $10.62 on the upside. A MCRB long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current MCRB IV rank near 29.31% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on MCRB at 132.70%. As a Healthcare name, MCRB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MCRB-specific events.
MCRB straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MCRB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MCRB alongside the broader basket even when MCRB-specific fundamentals are unchanged. Always rebuild the position from current MCRB chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on MCRB?
- A straddle on MCRB is the straddle strategy applied to MCRB (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With MCRB stock trading near $7.69, the strikes shown on this page are snapped to the nearest listed MCRB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are MCRB straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the MCRB straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 132.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a MCRB straddle?
- The breakeven for the MCRB straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MCRB market-implied 1-standard-deviation expected move is approximately 38.04%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on MCRB?
- Straddles on MCRB are pure-volatility plays that profit from large moves in either direction; traders typically buy MCRB straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current MCRB implied volatility affect this straddle?
- MCRB ATM IV is at 132.70% with IV rank near 29.31%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.